for a phase three trial of a lung cancer treatment.
While the drug compared well to a competitor on one endpoint, the data for overall survival was "not mature" and pointed toward to the results being not statistically significant, AstraZeneca said in a press release. The trial will continue, according to the company.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Fuente: MarketWatch - 🏆 3. / 97 Leer más »
Recession will take shine off stocks' AI-fueled rally in H2: HSBCUS stocks face a painful rest of 2023 with a recession set to take the shine off the AI-fueled rally, HSBC says
Fuente: BusinessInsider - 🏆 729. / 51 Leer más »